The dawn of the liquid biopsy in the fight against cancer

Irma G. Domínguez-Vigil; Ana K. Moreno-Martínez; Julia Y. Wang; Michael H. A. Roehrl; Hugo A. Barrera-Saldaña

doi:10.18632/oncotarget.23131

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

The dawn of the liquid biopsy in the fight against cancer

Irma G. Domínguez-Vigil, Ana K. Moreno-Martínez, Julia Y. Wang, Michael H. A. Roehrl _ and Hugo A. Barrera-Saldaña

PDF | HTML | How to cite

Oncotarget. 2018; 9:2912-2922. https://doi.org/10.18632/oncotarget.23131

Metrics: PDF 3794 views | HTML 12809 views | ?

Abstract

Irma G. Domínguez-Vigil1, Ana K. Moreno-Martínez1,2, Julia Y. Wang3, Michael H. A. Roehrl4 and Hugo A. Barrera-Saldaña1,5

1Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina de la Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México

2Genetics Laboratory, Vitagénesis, Monterrey, Nuevo León, México

3Curandis Laboratories, New York, NY, USA

4Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

5TecSalud, Tecnológico de Monterrey, San Pedro Garza García, Nuevo León, México

Correspondence to:

Michael H. A. Roehrl, email: [email protected]

Hugo A. Barrera-Saldaña, email: [email protected]

Keywords: liquid biopsy; cfDNA; ctDNA; early detection; diagnostics

Received: October 17, 2017 Accepted: November 10, 2017 Published: December 08, 2017

ABSTRACT

Cancer is a molecular disease associated with alterations in the genome, which, thanks to the highly improved sensitivity of mutation detection techniques, can be identified in cell-free DNA (cfDNA) circulating in blood, a method also called liquid biopsy. This is a non-invasive alternative to surgical biopsy and has the potential of revealing the molecular signature of tumors to aid in the individualization of treatments. In this review, we focus on cfDNA analysis, its advantages, and clinical applications employing genomic tools (NGS and dPCR) particularly in the field of oncology, and highlight its valuable contributions to early detection, prognosis, and prediction of treatment response.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23131

Publication Alerts

Reviews:

The dawn of the liquid biopsy in the fight against cancer

Abstract